HITIQ Eyes Sport, Defence and Insurance as Retail Sales Surge 223%
From validation to deployment — HITIQ’s multi-pathway commercial strategy takes shape
In its May/June 2026 non-deal roadshow presented across Perth, Melbourne, Singapore and the United States, HITIQ Limited (ASX: HIQ) outlined a business that has moved beyond technology validation into active commercial deployment. Management presented a single validated intra-oral biosensor core now being deployed across sport, defence, insurance and high-risk environments. Retail sales growth of 223% from Q2 to Q3 was positioned as the lead signal of emerging commercial momentum.
When big ASX news breaks, our subscribers know first
The problem HITIQ is solving — and why it’s urgent now
Objective head impact measurement is still missing at scale
Across sport, defence and institutional settings, head impact exposure continues to be assessed through observation, self-reporting and delayed symptom recognition. The scale of the problem, as presented in the roadshow, is significant:
- 69M Global TBI cases per year worldwide
- 4.8M US TBI emergency presentations annually
- 200K Australian TBI cases per year
- 91% of CT scans show no clinically significant finding
As the presentation states directly: “The problem is no longer awareness. The problem is objective measurement.”
Why intra-oral biosensing wins the physics argument
Intra-oral placement positions the sensor closer to the skull base than any external wearable, reducing movement noise and improving signal fidelity under load. For investors unfamiliar with the technology, this means readings are less distorted by the movement of helmets, hair or skin, producing data that more accurately reflects what the brain experiences during an impact.
The presentation included a direct comparison of HITIQ’s intra-oral approach against alternative measurement methods:
| Criterion | HITIQ Intra-Oral | Helmet Sensors | Wearables | Manual Protocols |
|---|---|---|---|---|
| Proximity to skull base | ✔ Closest coupling | Distant — fit variation | Surface only | N/A |
| Movement interference | ✔ Minimal | High — helmet shift | High — skin/hair noise | N/A |
| Signal fidelity | ✔ High | Moderate | Low–moderate | Subjective |
| Audit-ready data | ✔ Objective | Partial | Partial | ❌ No |
| Reproducibility | ✔ High | Variable | Variable | ❌ Low |
The technology’s validation credentials, as cited in the presentation, include:
- 93.6% sensitivity — Virginia Tech Helmet Lab
- 98.3% positive predictive value — Field et al., University of Canberra
- 5,000+ devices deployed globally
- SAHMRI and Adelaide University active research study combining smart mouthguard data, advanced brain MRI and cognitive testing
How HITIQ is building commercial momentum across four pathways
Retail traction and the consumer adoption engine
The retail rollout is gaining early traction, with management citing 223% sales growth from Q2 to Q3 as evidence of improving consumer adoption. Current and pipeline channels include:
- Rebel Sport flagship rollout
- hitiq.com direct-to-consumer
- Chemist Warehouse marketplace pathway
- Amazon pathway under evaluation
Athlete-led content is also generating measurable demand signals, with Ebony Marinoff content reaching 98,926 views and Jamal Fogarty content generating 63,811 views organically. Management presented these figures as validation of athlete-driven consumer interest rather than paid reach.
Ebony Marinoff, AFLW Premiership Player
“I trust PROTEQT at the elite level because brain health matters every time you play.”
Insurance, defence and institutional pathways emerging
Beyond retail, the presentation outlined three higher-value adoption pathways that management characterised as the scalable institutional layer of the business.
On insurance, the roadshow highlighted the deaths of two Japanese boxers on the same fight card in 2025, and the subsequent British Journal of Sports Medicine (BJSM) call for boxing to shift from subjective observation to objective, technology-enabled monitoring. Instrumented mouthguards were named as part of the recommended future safety stack. Separately, Sportscover has integrated instrumented head-impact technology into its sports insurance offering, which the presentation described as a clear market signal. The central thesis presented: once head impact exposure can be measured, relying solely on observation becomes harder to defend legally and clinically.
On defence, the presentation confirmed that trials are pending across multiple military jurisdictions globally, with a data sovereignty commitment covering domestic storage, role-based access and audit-ready infrastructure. Management used measured language — these remain pending pathways rather than active contracts.
New product extensions Cortex for Teams and Synapse for Schools were positioned as the software and workflow layer that converts hardware into institutional infrastructure:
- Cortex for Teams: session review, impact classification, longitudinal exposure monitoring, reporting for medical and welfare staff, and structured data pathways
- Synapse for Schools: athlete status dashboards, threshold breach visibility, recommended next steps, return-to-play oversight, and duty-of-care documentation
On international expansion, the presentation outlined three active pathways:
- United States: regulatory approvals process underway, initial discussions with “big box” retailers, active pathway across schools, sport, insurance and institutions
- UK/Europe: distribution partner discussions progressing, with defence-aligned opportunities under discussion
- Winter Olympics: over 100 units deployed, with research results pending
The next major ASX story will hit our subscribers first
The investment case — one biosensor platform, compounding market opportunity
Corporate snapshot
- ASX: HIQ
- Share price: A$0.013
- Market cap: A$9.83M
- Shares on issue: 756.22M
- Major shareholder: Harmil Angel Investments — 284.52M shares (37.76%), noted in the presentation as a continued backer through the next phase of growth
Leadership and roadshow schedule
The board brings a blend of governance, commercial and financial experience. Executive Chairman Earl Eddings is a former Chair of Cricket Australia and Director of the International Cricket Council. Chief Commercial Officer Damien Hawes joins from Catapult Group International, where he served as Head of League Wide and Media Partnerships. The management team is supported by advisors including neuroscientist Dr Martin Lang and former Hockeyroo Kalindi Commerford.
The roadshow schedule as presented:
- Perth — 12 May
- Melbourne — 15 May
- Singapore — 4 June
- USA — June 2026
The closing thesis presented to investors is straightforward: one validated biosensor core, deployed across multiple vessels and environments, generating compounding data value across sport, defence, insurance and research. Management presented this as a deployment story grounded in validated technology, with the institutional pathways — insurance, defence and education — representing the longer-term commercial layer above a retail base that is beginning to demonstrate measurable traction.
Don’t Miss the Next ASX Healthcare Breakout
Big News Blast delivers FREE breaking ASX healthcare and tech news to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ subscribers staying ahead of the market. Click the “Free Alerts” button to start receiving alerts the moment news breaks.